Palvella Therapeutics (PVLA) Total Current Liabilities (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Total Current Liabilities data on file, last reported at $9.1 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 1.47% year-over-year to $9.1 million in Q1 2026; TTM through Mar 2026 was $9.1 million, a 1.47% increase from a year earlier, with the FY2025 full-year figure at $11.3 million, down 5.77% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $9.1 million, down from $11.3 million in the prior quarter.
• Over the last five years, Total Current Liabilities for PVLA reached as high as $42.9 million in Q1 2023 and fell as low as $2.4 million in Q4 2023.
• Historically, Total Current Liabilities has averaged $19.6 million across 5 years, with a median of $11.3 million in 2025.
• Across the five-year window, Total Current Liabilities slumped 93.55% in 2023 and jumped 410.08% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $36.6 million in 2022, then slumped by 93.55% to $2.4 million in 2023, then soared by 410.08% to $12.0 million in 2024, then fell by 5.77% to $11.3 million in 2025, then retreated by 19.65% to $9.1 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $9.1 million in Q1 2026, $11.3 million in Q4 2025, and $10.3 million in Q3 2025.